NeuroSense Therapeutics Ltd. will present new clinical and biomarker data for its investigational drug PrimeC for the treatment of Amyotrophic Lateral Sclerosis (ALS) at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen. The presentation will take place on March 19, 2026, as part of the symposium “Mechanisms and Therapeutics in the ALS-FTD Spectrum.”
Dr. Christian Lunetta will present the results of the Phase 2b PARADIGM study under the title “From PARADIGM to PARAGON” and explain how they have influenced the planning of the global Phase 3 PARAGON study. PrimeC is an orally administered, extended-release combination of ciprofloxacin and celecoxib and targets multiple disease-relevant mechanisms in ALS.
The Phase 3 PARAGON study is designed as a multinational, randomized, double-blind, placebo-controlled trial. It aims to further evaluate the safety and efficacy of PrimeC in slowing disease progression. NeuroSense is in close communication with regulatory authorities to advance PrimeC toward potential market approval.
PrimeC targets the complex pathological processes in ALS, a progressive neurodegenerative disease that leads to complete paralysis and death within two to five years of diagnosis. More than 5,000 people are newly diagnosed each year in the U.S. alone. NeuroSense is developing combination therapies that target multiple disease-relevant pathways.
